Business
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trials BOSTON, June 06, 2023 (GLOBE NEWSWIRE)
About this update from Transcode Therapeutics, Inc.
[{"type":"text","content":"Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trials\nBOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat cancer, today announced acceptance for publication by Frontiers in Molecular Biosciences of a preclinical study using TransCode’s lead therapeutic candidate, TTX-MC138, in glioblastoma multiforme (GBM). The findings of this study support further development of TTX-MC138 for the treatment of GBM by identifying a potentially successful combination treatment protocol using TTX-MC138 with temozolomide (TMZ), currently the standard-of-care therapeutic. Treatment of human glioblastoma cells implanted in animals with the TTX-MC138 analogue, MN-anti-miR10b, inhibited tumor cell growth and induced cell death. When combined with a sub-therapeutic dose of TMZ in a sequence-specific protocol, MN-anti-miR10b enhanced the cell-killing ability of TMZ resulting in highly successful inhibition of tumor cell survival and invasiveness. GBM is the most common and aggressive form of brain tumors. The prognosis for patients with GBM is poor despite advances in standard-of-care therapy. The 5-year survival rate has remained unchanged over the past 30 years. There is an urgent unmet need to develop more effective therapies. TTX-MC138 is designed to inhibit the oncogenic RNA, microRNA-10b, described as the master regulator of cancer progression in a number of advanced solid tumors. TransCode believes that TTX-MC138 could be used as a treatment for many of these cancers. In a preclinical model of pancreatic adenocarcinoma, administration of TTX-MC138 as monotherapy resulted in complete responses, manifested as regression without recurrence, in 40% of treated animals. This study comes on the heels of preclinical studies in breast cancer demonstrating complete regressions of metastatic disease. In addition to murine models of cancer, TTX-MC138 was successfully delivered and demonstrated preliminary efficacy in a case study of spontaneous feline mammary carcinoma. Frontiers in Molecular Biosciences is a leading journal in its field with more than 22,000 citations and 11 million views across 3,200 articles. The study to appear in Frontiers in Mo...